In the relentless battle against antibiotic-resistant bacteria, scientists have developed a clever "two-key" strategy to defeat some of the most dangerous superbugs.
Antimicrobial resistance (AMR) is one of the most pressing global health threats of our time. In 2021 alone, bacterial AMR was linked to approximately 4.71 million deaths worldwide 3 . Among the most challenging pathogens are extensively drug-resistant (XDR) Gram-negative bacteria - superbugs that have evolved defenses against nearly all our available antibiotics 1 2 .
Deaths linked to AMR in 2021 3
The problem is particularly acute with bacteria that produce carbapenemases, enzymes that dismantle carbapenem antibiotics - often our last line of defense 2 . In Indian intensive care units, for example, Gram-negative organisms are frequently carbapenem-resistant, creating life-threatening treatment challenges 4 .
Scientists have devised an ingenious approach that combines two antibiotics: ceftazidime-avibactam (CZA) and aztreonam (ATM). Each drug holds a key to bypass different bacterial defense systems:
Combines an antibiotic with a beta-lactamase inhibitor that protects against serine-based enzymes (like OXA-48) but is vulnerable to metallo-beta-lactamases 6 .
Remains stable against metallo-beta-lactamases (like NDM) but can be hydrolyzed by other beta-lactamases 6 .
When used together, each drug covers the weakness of the other, creating a comprehensive defense against these formidable pathogens 6 .
To determine whether this combination will work against specific bacterial strains, clinical laboratories use sophisticated synergy testing methods. One crucial experiment demonstrates how researchers validate this approach.
In a comprehensive 2023 study, researchers tested the CZA-ATM combination against 100 carbapenem-resistant isolates of Klebsiella species and E. coli . These weren't ordinary resistant bacteria - 76.25% of the Klebsiella isolates were extensively drug-resistant (XDR, resistant to all but two or fewer antibiotic classes) and 18.75% were pan drug-resistant (PDR, resistant to all antibiotic classes) .
Bacterial suspensions were adjusted to the 0.5 McFarland standard - a specific turbidity that standardizes the number of bacteria.
The bacterial suspension was uniformly streaked over Mueller Hinton agar plates (the standard medium for antibiotic testing).
A ceftazidime-avibactam E-test strip was placed on the agar, with an aztreonam disc positioned 15 mm away, centered parallel to the sensitivity breakpoint of the CZA E-test strip.
Plates were incubated at 37°C for 16-18 hours - the standard time for bacterial growth.
Researchers looked for two signs of synergy:
The findings were striking: the combination showed synergy in 98.8% of Klebsiella species and 95% of E. coli isolates. Most significantly, all 16 pan drug-resistant isolates showed synergy - meaning this combination worked even against bacteria resistant to every other antibiotic .
| Bacterial Species | Number of Isolates Tested | Isolates Showing Synergy | Percentage Showing Synergy |
|---|---|---|---|
| Klebsiella species | 80 | 79 | 98.8% |
| E. coli | 20 | 19 | 95.0% |
| Total | 100 | 98 | 98.0% |
This demonstrates that the two-key approach can restore susceptibility to antibiotics that would otherwise be useless against these superbugs.
The promising laboratory findings are supported by real-world clinical studies. A 2023 retrospective analysis compared outcomes between patients with CRE bacteremia treated with polymyxin-based therapy versus CAZ-AVI-based therapy (with or without aztreonam) 4 .
The results were compelling: the CAZ-AVI-based group was 66% less likely to experience day 14 mortality and 67% less likely to experience day 28 mortality compared to the polymyxin group 4 . Additionally, the incidence of nephrotoxicity (kidney damage) was significantly higher in the polymyxin group, making the CAZ-AVI-based approach both more effective and safer 4 .
| Outcome Measure | Polymyxin-Based Therapy | CAZ-AVI-Based Therapy | Statistical Significance |
|---|---|---|---|
| Day 14 Mortality | Higher | 66% reduction | p = 0.048 |
| Day 28 Mortality | Higher | 67% reduction | p = 0.039 |
| Nephrotoxicity (Kidney Damage) | Significantly higher | Lower | p = 0.017 |
Several laboratory techniques are available to detect antibiotic synergy, each with advantages and limitations:
Uses antibiotic discs and strips placed at specific distances on agar plates .
Simple, cost-effective, easy to interpret .
Less quantitative than other methods.
Measures bacterial killing over time when exposed to antibiotic combinations.
Considered a reference method, provides kinetic data.
Technically demanding, resource-intensive 9 .
The combination of ceftazidime-avibactam and aztreonam represents a breakthrough in our approach to tackling extensively drug-resistant Gram-negative infections. Rather than developing entirely new antibiotics - a slow and costly process - this strategy uses existing drugs in smarter combinations.
Combining existing antibiotics to overcome resistance mechanisms
Proven effective against even pan drug-resistant isolates
Real-world evidence shows improved patient outcomes
As research continues, synergy testing methods are becoming more refined and accessible, even for resource-limited settings 1 6 . Simple disk methods can now guide effective therapeutic decisions, potentially saving countless lives 1 .
In the relentless evolutionary arms race between humans and bacteria, the two-key strategy offers a powerful new weapon - demonstrating that sometimes, the most innovative solutions come not from creating something entirely new, but from combining what we already have in clever, unexpected ways.